Anlotinib Hydrochloride In Combination With Penpulimab (AK105) in Patients With Chemo-refractory Metastatic Colorectal Cancer, Open, Single Arm,Exploratory Clinical Trial(ALTER-C003)
Latest Information Update: 06 Mar 2024
At a glance
- Drugs Catequentinib (Primary) ; Penpulimab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms ALTER-C003
- 03 Nov 2021 Status changed from not yet recruiting to recruiting.
- 27 Jul 2021 New trial record